Scope
This House summary covers screening, assessment and selected treatment decisions in the AAO diabetic-retinopathy Preferred Practice Pattern. Retinopathy stage, whether macular oedema involves the centre, visual acuity and the likelihood of reliable follow-up all influence management. It is a focused clinical guide, not a complete injection or retinal-surgery protocol.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Screening and systemic care
- For type 1 diabetes without retinopathy, start annual dilated retinal examinations 5 years after diabetes onset. For type 2 diabetes, examine at diagnosis and at least annually thereafter. Abnormal findings require an individualized, often shorter interval. [1]
- Explain that good vision and absence of symptoms do not exclude significant retinopathy. Retinal examinations remain necessary, and early detection allows treatment before avoidable visual loss. [1]
- For pre-existing diabetes, arrange an examination before planned pregnancy and during the first trimester, with subsequent review based on retinopathy severity. Gestational diabetes alone does not require a retinopathy examination during pregnancy. Pubertal patients need increased vigilance. [1]
- Coordinate safe glucose, blood-pressure and lipid control with the diabetes clinician. Warn that rapid tightening of glucose control can initially worsen retinopathy; communicate ocular findings when systemic treatment changes. [1]
- Diabetic retinopathy alone is not a reason to stop aspirin prescribed for another medical indication: the guideline does not recommend changing medically indicated aspirin because of diabetic retinal disease. [1]
Examination and imaging
- Record diabetes duration and previous control, medications, systemic disease, pregnancy, ocular treatment and the onset or speed of visual loss. Examine visual acuity, pupils, intraocular pressure, anterior segment, dilated retina and vitreous. [1]
- If iris neovascularization is suspected or intraocular pressure is elevated, perform gonioscopy before dilation to assess the anterior chamber angle. Iris new vessels are best recognized before dilation. [1]
- Classify retinopathy and macular oedema in both eyes. Distinguish centre-involved from non-centre-involved oedema, which can occur at any retinopathy stage; use these findings and systemic control to plan treatment and review. [1]
- Use OCT to quantify retinal thickening, monitor macular oedema and identify vitreomacular traction or another macular cause of reduced vision. Interpret thickness with visual acuity because the two are not consistently correlated. [1]
- Do not perform fluorescein angiography routinely at every diabetes examination. It can clarify unexplained visual loss, other macular disease, nonperfusion or persistent neovascularization. Use ultrasound when haemorrhage or another media opacity prevents retinal assessment. [1]
Macular oedema treatment
- For centre-involved diabetic macular oedema with visual loss, intravitreal anti-VEGF treatment is the principal first-line treatment, having displaced focal laser monotherapy. Choose the product jointly with the patient rather than assuming all products or regimens are interchangeable. [1]
- For centre-involved oedema with good visual acuity, treatment can reasonably be deferred until acuity is affected, described here as 20/30 or worse. Examine these patients every 2–4 months; observation means planned surveillance, not discharge. [1]
- Individualize anti-VEGF retreatment using both visual acuity and OCT response. Treat-and-extend is an alternative approach that adjusts the visit interval to response; this summary does not substitute a universal injection schedule for a product-specific protocol. [1]
- Intravitreal corticosteroids are generally second-line treatment for diabetic macular oedema, particularly in phakic eyes, because of cataract progression and raised intraocular pressure. They may help selected eyes with suboptimal or absent anti-VEGF response. [1]
- Use topical povidone iodine for intravitreal injections. Routine antibiotic drops before or after injection are not recommended because they do not reduce endophthalmitis risk and increase resistant ocular flora. [1]
Retinopathy progression and proliferative disease
- A normal retina or rare microaneurysms generally warrants annual review. For mild-to-moderate nonproliferative disease without macular oedema, the narrative recommends reassessment within 6–12 months. Disease progression or treatment changes can justify closer review. [1]
- Severe nonproliferative or non-high-risk proliferative retinopathy needs close review, described in the narrative as 2–4 months. Early panretinal photocoagulation can be considered, particularly for very severe nonproliferative disease or non-high-risk proliferative disease. [1]
- Most eyes with high-risk proliferative retinopathy should receive panretinal photocoagulation promptly. If laser is selected, full panretinal treatment is the proven approach; partial or limited treatment is not recommended. [1]
- Anti-VEGF alone can be considered for proliferative retinopathy when follow-up is reliable. Choose cautiously: patients lost to follow-up after injections have worse visual and anatomical outcomes than those treated with panretinal photocoagulation. [1]
- Do not postpone panretinal photocoagulation in high-risk proliferative disease because of associated oedema. Anti-VEGF and laser may be given together; consider combined treatment at the first session when centre-involved oedema is also present. [1]
- Consider vitrectomy for nonclearing vitreous haemorrhage, tractional detachment threatening or involving the macula, combined rhegmatogenous/tractional detachment, or dense premacular subhyaloid haemorrhage. Follow vitreous haemorrhage with serial ultrasound to detect tears or detachment. [1]
Ongoing care and visual rehabilitation
- Communicate eye findings to the clinician managing diabetes and help patients plan repeated visits. For functionally limiting visual impairment, offer vision rehabilitation and social support; consider counselling or vocational support when anxiety, depression or loss of independence affects daily life. [1]
Limitations and use
- This is a focused selection from the AAO Preferred Practice Pattern, not a complete drug, laser or vitrectomy protocol. Individual drug approvals, availability and reimbursement require local checking.
- Retinopathy severity, oedema, visual acuity, pregnancy and reliable follow-up modify treatment and review intervals. The full disease-stage tables and high-risk classification criteria should be consulted for an individual treatment plan.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diabetic retinopathy
Selected recommendation material consulted
Publication details
- Issuing organisation
- AAO
- First published
- 7 February 2025
- Resource type
- Preferred Practice Pattern guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.